Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro.
Antiviral Res
; 190: 105075, 2021 06.
Article
in English
| MEDLINE | ID: covidwho-1290345
ABSTRACT
The emerging SARS-CoV-2 infection is the cause of the global COVID-19 pandemic. To date, there are limited therapeutic options available to fight this disease. Here we examined the inhibitory abilities of two broad-spectrum antiviral natural products chebulagic acid (CHLA) and punicalagin (PUG) against SARS-CoV-2 viral replication. Both CHLA and PUG reduced virus-induced plaque formation in Vero-E6 monolayer at noncytotoxic concentrations, by targeting the enzymatic activity of viral 3-chymotrypsin-like cysteine protease (3CLpro) as allosteric regulators. Our study demonstrates the potential use of CHLA and PUG as novel COVID-19 therapies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Benzopyrans
/
Hydrolyzable Tannins
/
Coronavirus 3C Proteases
/
SARS-CoV-2
/
Glucosides
Limits:
Animals
Language:
English
Journal:
Antiviral Res
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS